PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jonathan E. Rosenberg, Daniel Peter Petrylak, Michiel Simon Van Der Heijden, Andrea Necchi, Peter H. O'Donnell, Yohann Loriot, Margitta Retz, Jose Luis Perez-Gracia, Joaquim Bellmunt, Petros Grivas, Richard Wayne Joseph, Lawrence Fong, Edward E. Kadel, Zachary Boyd, Dorothee Nickles, Garrett Michael Frampton, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, Thomas Powles
Institutions: Memorial Sloan Kettering Cancer Center, Yale University, The Netherlands Cancer Institute, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Chicago, University of Chicago Medicine Comprehensive Cancer Center, Institut Gustave Roussy, TUM Klinikum, Technical University of Munich, Clinica Universidad de Navarra, Dana-Farber Cancer Institute, Cleveland Clinic, Mayo Clinic in Florida, University of California, San Francisco, Genentech, Foundation Medicine (United States), Royal Free London NHS Foundation Trust, Barts Health NHS Trust, Barts Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2625718262
